AGN News 133.92 Allergan Inc (AGN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Allergan Inc (AGN) 133.92 $AGN

Glaxo Looking into Misconduct Charges - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:35PM CDT
GlaxoSmithKline recently responded to investigations and charges of misconduct in Jordan and Lebanon.

Roche Meets Sales Estimates in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:00PM CDT
Sales of $13.0 billion were in line with the Zacks Consensus Estimate in the first quarter.

Dr. Rian A. Maercks Announces Appointment to Elite ASCENT National Advisory Panel in Plastic Surgery, Comprised of Top 25 Leaders in Innovative Plastic Surgery in the U.S.
PR Newswire - Thu Apr 17, 7:45AM CDT
In recognition of expertise and interest in delivering the most innovative aesthetically superior treatment options, Dr. Rian A. Maercks has been appointed to the elite Allergan ASCENT advisory board of the top 25 leaders in plastic surgery in the U.S.

TauTona Group Sells Aline HA(R) to Allergan
Marketwire - Thu Apr 17, 7:30AM CDT
TauTona Group, a medical device incubator and investment fund focused on the rapid development of innovative medical products, today announced that its wholly-owned subsidiary Aline Aesthetics has completed the sale of its Aline hyaluronic acid (HA) thread technology to Allergan, Inc. The Aline HA technology is under development for use as a dermal filler.

Stocks On Track For Third Gain; Allergan Rises
at Investor's Business Daily - Wed Apr 16, 1:54PM CDT
Stocks continued to hold near their session highs Wednesday afternoon and had little reaction to the Fed's beige book. The Dow Jones industrial average and the Nasdaq rose 0.8% each, while the S&P 500 climbed 0.7%. All three were on pace for a third...

Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 11:41AM CDT
Abbott Laboratories reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents.

Trade-Ideas: Allergan (AGN) Is Today's Momo Momentum Stock
at The Street - Wed Apr 16, 8:46AM CDT
Trade-Ideas LLC identified Allergan (AGN) as a momo momentum candidate

Another Earnings Beat from J&J, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 1:17PM CDT
J&J's earnings streak continues with the company reporting strong first quarter results and raising its guidance for the year.

Top-of-Mind Companies in Facial Injectable and Laser/Energy Device Markets Are Similar in Europe and Asia
PR Newswire - Tue Apr 15, 9:00AM CDT
Decision Resources Group, in collaboration with IMCAS (International Master Course on Aging Skin), finds that the top-of-mind companies in each of the botulinum toxin (BTX), dermal filler and laser/energy device markets are similar in Europe and in Asia. Not surprisingly, Allergan's BOTOX Cosmetic continues to be the top-of-mind BTX brand in both Asia and Europe, with Allergan's JUVEDERM and Galderma's Restylane both having high recognition among dermal filler brands. Lumenis came out on top for laser/energy devices in both regions.

3 Big-Volume Stocks in Breakout Territory
at The Street - Tue Apr 15, 7:23AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.

Global Retinal Vein Occlusion Therapeutics Pipeline Review 2014 - Analysis of 5 Companies and 6 Drug Profiles
M2 - Tue Apr 15, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jr9qs5/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinal Vein Occlusion and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinal Vein Occlusion products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Retinal Vein Occlusion pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Retinal Vein Occlusion - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - NicOx S.A. - ThromboGenics NV Drug Profiles - fluocinolone acetonide - beclomethasone dipropionate - ranibizumab - ocriplasmin - NCX-434 - NCX-422 For more information visit http://www.researchandmarkets.com/research/jr...tinal_vein

After Yesterday's Rally of 2.55% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Apr 14, 3:40PM CDT
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $120.72 to a high of $124.46. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $121.96 on volume of 7.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Next Resistance Level for Allergan (AGN) is $125.58
Comtex SmarTrend(R) - Mon Apr 14, 12:30PM CDT
Shares of Allergan (AMEX:AGN) opened today above their pivot of $119.62 and have already reached the first level of resistance at $123.23. Analysts will be watching for a cross of the next upside pivot targets of $125.58 and $131.54.

Regulatory Approvals, Earnings and Conference Call Schedules, and Stock Price Updates - Analyst Notes on Teva, Allergan, Boston Scientific, Covidien and Thermo Fisher
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Allergan Inc. (NYSE: AGN), Boston Scientific Corporation (NYSE: BSX), Covidien Plc (NYSE: COV) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1089-100free.

Active Equities under the Scanner -- Research on Allergan, Visa, Starbucks, and Home Depot
PR Newswire - Mon Apr 14, 7:00AM CDT
The trading session on Friday, April 11, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,026.75, down 0.89% and the NASDAQ Composite closed at 3,999.73, down 1.34%. The S&P 500 finished the session 0.95% lower at 1,815.69. The losses were broad based as all the ten sectors ended the session in negative. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Allergan Inc. (NYSE: AGN), Visa Inc. (NYSE: V), Starbucks Corp. (NASDAQ: SBUX) and The Home Depot Inc. (NYSE: HD). Free technical research on AGN, V, SBUX and HD can be downloaded upon signing up at:

Why Rambus, Allergan, and JAKKS Pacific Rose Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Apr 11, 7:05PM CDT
Friday didn't turn out to be quite as bad a day for the stock market as Thursday was, with major-market benchmarks ending the day down around 1% to 1.5% instead of the up to 3% losses that we saw yesterday. Nevertheless, continued weakness in some...

NYSE stocks posting largest percentage increases
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:

Abbott Labs Progresses with Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:40PM CDT
Abbott Laboratories (ABT) announced that it has completed enrollment of three clinical trials on Absorb, a drug-eluting coronary bioresorbable vascular scaffold (BVS).

3 Health Care Stocks Moving The Sector Upward
at The Street - Fri Apr 11, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 67

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 67

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 79

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading

Top 5 Most Recently Viewed Articles

Gate Ventures Backs Japanese Web3 Gaming Innovator double jump.tokyo

Updated Category News Views 276

Gate Ventures Invests in double jump.tokyo Gate Ventures is making a significant impact in the blockchain and gaming sectors with its latest investment in double jump.tokyo Inc., a prominent player in Web3 gaming based in Japan. This strategic investment is part of a larger $10 million funding round led by SBI Investment. This backing represents more than just financial...

Continue Reading
Insights from Gridwise's Gig Mobility Report Highlight Trends

Updated Category News Views 1754

Gridwise Annual Gig Mobility Report Highlights The gig mobility industry is encountering significant challenges as economic conditions evolve. Consumers are feeling the pinch from rising prices, leading to resistance against fare increases. Moreover, driver wages are stagnating, which is causing utilization rates to remain low. As platforms strive for profitability, this...

Continue Reading
Esquire Financial Achieves Historic Stock Surge to $81.89

Updated Category News Views 124

Esquire Financial's Stock Reaches New Heights Esquire Financial Holdings Inc (NASDAQ: ESQ) has celebrated a remarkable achievement as its stock price reached an all-time high of $81.89 recently. This milestone reflects the company's strong financial health and market position, boasting a market capitalization of approximately $638 million. The surge in price signals a...

Continue Reading
Deck Commerce Shines as a Leader in Omnichannel Management

Updated Category News Views 199

Deck Commerce Emerges as a Leading Innovator In the competitive landscape of order management systems, Deck Commerce stands out as a beacon of innovation and excellence. Recently recognized by QKS Group's SPARK Matrix™ for 2025, the company has secured its position as both a leader and emerging innovator in the field. This accolade reflects Deck Commerce's dedication to...

Continue Reading
Porsche Penske Motorsport Celebrates Historic Victory

Updated Category News Views 343

Porsche Penske Motorsport Celebrates Historic Victory Porsche Penske Motorsport has achieved remarkable success at the prestigious 24 Hours of Daytona, clinching its second consecutive win. As the race unfolded, the familiar faces of Felipe Nasr, Nick Tandy, and Laurens Vanthoor led the No. 7 Porsche 963 to victory, marking a milestone as Porsche secured its 20th overall...

Continue Reading